Adding quality years to life
We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic Hematopoietic Cell Transplantation (HCT) and CAR-T cell therapy.
Our Vision
Our vision is to extend and enhance the quality of life for patients radically by transforming the treatment of hematologic malignancies. We are committed to pioneering innovative therapies that harness the power of allogeneic hematopoietic cell transplantation (HCT). Through the development of our investigational drug, mocravimod, we aim to address critical challenges in current treatments by enhancing the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD). Our ultimate goal is to deliver a therapy that not only improves survival rates but also ensures safer and more effective long-term outcomes for patients with hematological malignancies, specifically acute myeloid leukemia.
The impact of acute Myeloid Leukemia
New estimated cases of leukemia (all kinds) in the US
New estimated cases of AML in the US
Estimated deaths from AML in the US
*From the American Cancer Society 2020
Hematopoietic
Cell
Transplantation
(HCT)
Mocravimod
Our Pipeline
CAR T cell therapy
MO-TRANS Phase 3 Study
Director Statement
Applying mocravimod’s well-described, safe mode of action to hematological malignancies will bring a game changing treatment to patients suffering from devastating blood cancers”
Florent Gros – Founder, CEO of Priothera
“Mocravimod is an outstanding, well-characterized and well-behaved S1P receptor modulator that is well-suited for clinical development and commercial manufacturing. Mocravimod has the potential to be a best-in-class therapy to ameliorate the morbidity and mortality associated with HCT for AML.”
Dhaval Patel – Director of Priothera, CSO of Sana Biotechnology, formally EU Research Head Novartis
At Priothera, we are committed to integrating ESG principles across our business. From our local efforts in St. Louis, France, to global initiatives in Madagascar, we integrate sustainable practices, ethical governance and positive social impact in everything we do.
Academic partners:
Charité Universitätsmedizin Berlin, Berlin, Germany